title: [Aspirin therapy for cardiovascular prevention in the diabetic patient: what have we learned from the evidence?].
abstract: Diabetes mellitus markedly increases the risk of cardiovascular diseases, with an especially elevated relative risk among women. Aspirin prescription is mandatory in secondary prevention, even if the protection by aspirin appears less efficacious in diabetic than in non-diabetic patients. In primary prevention, available data are paradoxically rather scarce, but also suggest a less effective prevention when diabetes is present. Aspirin remains the first antiplatelet agent in the diabetic population in all international guidelines of cardiovascular prevention although a higher daily dose may be proposed in this subgroup of patients (160-300 mg rather than 75-100 mg).
authors.affiliation: Université de Liège, Service de diabétologie, nutrition et maladies métaboliques, CHU SartTilman, B-4000 Liège I.
authors.forename: D A
authors.initials: DA
authors.lastname: Legrand
authors.forename: A J
authors.initials: AJ
authors.lastname: Scheen
mesh_terms: D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D048909:Diabetes Complications; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin